Nevertheless, we observed an increasing trend in converters (+0.5%) while the nonconverter group has a FEV 1 trend of −4.2% posttreatment with ALIS ( Table 5 ).
← all excerpts
Amikacin Liposomal Inhalation Suspension in the Treatment of <i>Mycobacterium abscessus</i> Lung Infection: A French Observational Experience.
1
—
—